CDKI-83
CDKI-83 is a potent CDK9 inhibitor. The compound shows effective anti-proliferative activity in human tumour cell lines with GI50 <1 μM, and is capable of inducing apoptosis in A2780 human ovarian cancer cells as determined by the activated caspase-3, Annexin V/PI double staining and accumulated cells at the sub-G1 phase of cellcycle. The research results suggest that combined inhibition of CDK9 and CDK1 may result in the effective induction of apoptosis and CDKI-83 has the potential to be developed as an anti-cancer agent.
1: Liu X, Lam F, Shi S, Fischer PM, Wang S. In vitro antitumor mechanism of a novel cyclin-dependent kinase inhibitor CDKI-83. Invest New Drugs. 2012 Jun;30(3):889-97. doi: 10.1007/s10637-011-9641-5. Epub 2011 Feb 18. PubMed PMID: 21331744.
| Chemical | |
|---|---|
| CAS Num | 1189558-88-0 |
| Chemical Formula | C21H23N7O3S2 |
| Molecular Weight | 485.58 |
| IUPAC Chemical Name | 4-(4-methyl-2-(methylamino)thiazol-5-yl)-2-((4-methyl-3-(morpholinosulfonyl)phenyl)amino)pyrimidine-5-carbonitrile |
| Exact Mass | 485.13038 |
| Elemental Analysis | C, 51.94; H, 4.77; N, 20.19; O, 9.88; S, 13.21 |
| Synonym | CDKI83; CDKI-83; CDKI 83. |
| Solubility | Soluble in DMSO, not in water |
| SMILES Code | N#CC1=CN=C(NC2=CC=C(C)C(S(=O)(N3CCOCC3)=O)=C2)N=C1C4=C(C)N=C(NC)S4 |
| Biological | |
| Targets and Effects | N/A |
| Pathways | Apoptosis |
| Physical | |
| Appearance | Solid powder |
| Purity | >98% (or refer to the Certificate of Analysis) |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| Storage Condition | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Shelf Life | >5 years if stored properly |
Mailing Address
Anba Pharma Company
3-H Gill Street, Suite 300
Woburn, MA 01801
United State
Our Contact Info.
Tel: 1+610-883-0668
Email: sales@AnbaPharma.com